Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00441142 · ClinicalTrials.gov registry record · Phase 1
Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors
A Phase 1 study, sponsored by Patrick Y. Wen, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 119
- Enrollment target
NCT00441142 is a Phase 1 study that has completed, run by Patrick Y. Wen, MD. The registered enrollment target is 119 participants.
The verdict
NCT00441142, a Phase 1 study, has completed, sponsored by Patrick Y. Wen, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 119 participants
- Enrollment target
Study Summary
Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. We will determine the highest dose of ZD6474 (Vandetanib) that can be given safely when combined with temozolomide (Temodar) and radiation therapy. Phase II: The purpose of this research study is to determine the efficacy of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. All subjects participating in this research study must NOT be taking a certain type of anti-seizure medication called enzyme inducing anticonvulsant drugs. These drugs include (but are not limited to) the following medications: Dilantin, Tegretol, Phenobarbital and trileptal.
Interventions
- RADIATION Radiation Therapy
- DRUG temozolomide
- DRUG ZD6474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2007-05-25 |
| Est. Completion | 2017-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00441142
The ClinicalTrials.gov registry entry for NCT00441142 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Y. Wen, MD, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT00441142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00441142 about?
NCT00441142 is a clinical study titled "Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors". Phase I: The purpose of this research study is to determine the safety of the combination treatment of ZD6474 (Vandetanib) with the standard therapy for glioblastomas and gliosarcomas, temozolomide (Temodar) and radiation therapy. This agent is investigational for the treatment of glioblastomas. We...
What is the current status of trial NCT00441142?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 119 participants. The study started on 2007-05-25. Estimated completion is 2017-10-10.
What interventions are being tested in trial NCT00441142?
The interventions under investigation include: Radiation Therapy (RADIATION), temozolomide (DRUG), ZD6474 (DRUG).
Who is sponsoring clinical trial NCT00441142?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.